A detailed history of Alliancebernstein L.P. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Alliancebernstein L.P. holds 636,914 shares of NBIX stock, worth $86.3 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
636,914
Previous 621,865 2.42%
Holding current value
$86.3 Million
Previous $85.6 Million 14.35%
% of portfolio
0.03%
Previous 0.03%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$114.58 - $153.15 $1.72 Million - $2.3 Million
15,049 Added 2.42%
636,914 $73.3 Million
Q2 2024

Aug 14, 2024

BUY
$130.86 - $143.19 $60.4 Million - $66.1 Million
461,642 Added 288.12%
621,865 $85.6 Million
Q1 2024

May 14, 2024

SELL
$130.4 - $143.74 $1.75 Million - $1.93 Million
-13,405 Reduced 7.72%
160,223 $22.1 Million
Q4 2023

Feb 14, 2024

BUY
$106.07 - $132.76 $2.64 Million - $3.3 Million
24,868 Added 16.72%
173,628 $22.9 Million
Q3 2023

Nov 14, 2023

BUY
$94.02 - $117.1 $1 Million - $1.25 Million
10,677 Added 7.73%
148,760 $16.7 Million
Q2 2023

Aug 15, 2023

SELL
$89.53 - $104.87 $1.19 Million - $1.39 Million
-13,266 Reduced 8.77%
138,083 $13 Million
Q1 2023

May 15, 2023

SELL
$94.11 - $123.02 $1.46 Million - $1.91 Million
-15,512 Reduced 9.3%
151,349 $15.3 Million
Q4 2022

Feb 14, 2023

BUY
$106.72 - $127.06 $1.25 Million - $1.49 Million
11,693 Added 7.54%
166,861 $19.9 Million
Q3 2022

Nov 15, 2022

BUY
$92.03 - $107.81 $601,968 - $705,185
6,541 Added 4.4%
155,168 $16.5 Million
Q2 2022

Aug 15, 2022

SELL
$75.79 - $100.07 $2.79 Million - $3.69 Million
-36,859 Reduced 19.87%
148,627 $14.5 Million
Q1 2022

May 13, 2022

BUY
$72.45 - $94.81 $1.59 Million - $2.08 Million
21,984 Added 13.45%
185,486 $17.4 Million
Q4 2021

Feb 14, 2022

SELL
$79.65 - $106.22 $617,128 - $822,992
-7,748 Reduced 4.52%
163,502 $13.9 Million
Q3 2021

Nov 10, 2021

BUY
$86.18 - $99.03 $1.58 Million - $1.81 Million
18,279 Added 11.95%
171,250 $16.4 Million
Q2 2021

Jul 30, 2021

SELL
$89.43 - $102.27 $534,344 - $611,063
-5,975 Reduced 3.76%
152,971 $14.9 Million
Q1 2021

May 06, 2021

BUY
$87.57 - $119.4 $8.82 Million - $12 Million
100,678 Added 172.78%
158,946 $15.5 Million
Q4 2020

Feb 08, 2021

SELL
$86.91 - $108.33 $55.6 Million - $69.3 Million
-639,914 Reduced 91.65%
58,268 $5.59 Million
Q3 2020

Nov 12, 2020

SELL
$96.16 - $135.15 $18.3 Million - $25.8 Million
-190,677 Reduced 21.45%
698,182 $67.1 Million
Q2 2020

Aug 13, 2020

SELL
$85.09 - $130.36 $20.8 Million - $31.9 Million
-244,961 Reduced 21.6%
888,859 $108 Million
Q1 2020

May 14, 2020

SELL
$75.11 - $113.76 $7.97 Million - $12.1 Million
-106,113 Reduced 8.56%
1,133,820 $98.1 Million
Q4 2019

Feb 18, 2020

SELL
$86.8 - $118.57 $928,933 - $1.27 Million
-10,702 Reduced 0.86%
1,239,933 $133 Million
Q3 2019

Nov 14, 2019

BUY
$83.82 - $101.5 $3.96 Million - $4.79 Million
47,231 Added 3.92%
1,250,635 $113 Million
Q2 2019

Aug 14, 2019

BUY
$72.24 - $91.27 $7.15 Million - $9.03 Million
98,945 Added 8.96%
1,203,404 $102 Million
Q1 2019

May 14, 2019

BUY
$69.31 - $91.53 $2.37 Million - $3.13 Million
34,243 Added 3.2%
1,104,459 $97.3 Million
Q4 2018

Feb 13, 2019

SELL
$68.32 - $124.36 $2.59 Million - $4.72 Million
-37,978 Reduced 3.43%
1,070,216 $76.4 Million
Q3 2018

Nov 08, 2018

SELL
$98.88 - $125.85 $5.61 Million - $7.14 Million
-56,706 Reduced 4.87%
1,108,194 $136 Million
Q2 2018

Aug 13, 2018

SELL
$75.3 - $105.99 $8,132 - $11,446
-108 Reduced 0.01%
1,164,900 $114 Million
Q1 2018

May 14, 2018

BUY
$75.88 - $92.43 $16.4 Million - $19.9 Million
215,680 Added 22.72%
1,165,008 $96.6 Million
Q4 2017

Feb 13, 2018

SELL
$58.53 - $77.59 $3.3 Million - $4.37 Million
-56,319 Reduced 5.6%
949,328 $73.7 Million
Q3 2017

Nov 13, 2017

BUY
$47.97 - $61.28 $48.2 Million - $61.6 Million
1,005,647
1,005,647 $61.6 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.